휴젤

145020KOSDAQ기초 의약물질 제조업

63.1 / 100

Reference Date: 2026-07-24

Financial Score27.5 / 40

News Sentiment20.6 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 6.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hujeel develops and manufactures biopharmaceuticals based on Clostridium botulinum type A toxin, and directly handles sales after merging with its subsidiary, Hujel Pharma, in 2018. Its major subsidiary, Acros, focuses on HA filler development and production. Both botulinum toxin and HA fillers have broad applications in medical and cosmetic fields.

Number of Employees

629people

Average Salary

64.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

18.49Industry Average 25.446.5Point

Lower than industry avg (good)

PBR

3.03Industry Average 1.260.0Point

2.4x industry avg (risky)

ROE

16.14Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

0.37Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20259.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲31.0% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 15.3% (improving, 3yr)

Detailed News Sentiment

16 totalPositive 16Neutral 0Negative 0Average Sentiment Score 82.5

Positive
휴젤, 인도 보톡스 시장 진출
휴젤의 인도 보톡스 시장 진출로 인해 중장기 성장 가능성이 높아져 긍정적인 전망을 받고 있다.
Positive
휴젤, 보툴리눔 톡신 ‘레티보’ 인도 진출…“올해 점유율 9% 달성 ...
휴젤의 보툴리눔 톡신 레티보가 인도 시장 진출로 인해 올해 점유율 확대 기대감이 높아져 긍정적인 영향을 받고 있다.
Positive
휴젤, 안전성 높인 HA 필러 '더채움 시그니처' 출시
휴젤의 신제품 '더채움 시그니처' 출시로 안전성 향상과 다양한 시술 적용 가능성이 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 241,500Won52-week high 360,00052-week low 214,000

1-month return2.0Point

1m -6.94% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral전환청구권행사2026-07-13
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-07-02
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-07-02
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-07-02